HRP20120695T1 - 8-supstituirani benzoazepini kao modulatori toll-u sličnog receptora - Google Patents
8-supstituirani benzoazepini kao modulatori toll-u sličnog receptora Download PDFInfo
- Publication number
- HRP20120695T1 HRP20120695T1 HRP20120695TT HRP20120695T HRP20120695T1 HR P20120695 T1 HRP20120695 T1 HR P20120695T1 HR P20120695T T HRP20120695T T HR P20120695TT HR P20120695 T HRP20120695 T HR P20120695T HR P20120695 T1 HRP20120695 T1 HR P20120695T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- compound according
- nr6r7
- alkynyl
- alkenyl
- Prior art date
Links
- -1 8-substituted benzoazepines Chemical class 0.000 title claims abstract 5
- 102000002689 Toll-like receptor Human genes 0.000 title 1
- 108020000411 Toll-like receptor Proteins 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 19
- 150000001875 compounds Chemical class 0.000 claims abstract 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract 10
- 125000003118 aryl group Chemical group 0.000 claims abstract 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract 8
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 6
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 6
- 239000001301 oxygen Substances 0.000 claims abstract 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 6
- 125000006413 ring segment Chemical group 0.000 claims abstract 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 6
- 239000011593 sulfur Substances 0.000 claims abstract 6
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract 4
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 4
- 235000010290 biphenyl Nutrition 0.000 claims abstract 4
- 239000004305 biphenyl Substances 0.000 claims abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 4
- 239000001257 hydrogen Substances 0.000 claims abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 4
- 125000001624 naphthyl group Chemical group 0.000 claims abstract 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- QSPOQCXMGPDIHI-UHFFFAOYSA-N 2-amino-n,n-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3h-1-benzazepine-4-carboxamide Chemical compound C1=C2N=C(N)CC(C(=O)N(CCC)CCC)=CC2=CC=C1C(C=C1)=CC=C1C(=O)N1CCCC1 QSPOQCXMGPDIHI-UHFFFAOYSA-N 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- ZYMPZUFXXOGLER-UHFFFAOYSA-N ethyl 2-amino-8-(4-methoxycarbonylphenyl)-3h-1-benzazepine-4-carboxylate Chemical compound C1=C2N=C(N)CC(C(=O)OCC)=CC2=CC=C1C1=CC=C(C(=O)OC)C=C1 ZYMPZUFXXOGLER-UHFFFAOYSA-N 0.000 claims 1
- HVLAVIBSYHIWBX-UHFFFAOYSA-N ethyl 2-amino-8-[4-(methylcarbamoyl)phenyl]-3h-1-benzazepine-4-carboxylate Chemical compound C1=C2N=C(N)CC(C(=O)OCC)=CC2=CC=C1C1=CC=C(C(=O)NC)C=C1 HVLAVIBSYHIWBX-UHFFFAOYSA-N 0.000 claims 1
- ZVMJXACINLNMLK-UHFFFAOYSA-N ethyl 2-amino-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3h-1-benzazepine-4-carboxylate Chemical compound C1=C2N=C(N)CC(C(=O)OCC)=CC2=CC=C1C(C=C1)=CC=C1C(=O)N1CCCC1 ZVMJXACINLNMLK-UHFFFAOYSA-N 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71000405P | 2005-08-19 | 2005-08-19 | |
PCT/US2006/032098 WO2007024612A2 (en) | 2005-08-19 | 2006-08-17 | 8-substituted benzoazepines as toll-like receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120695T1 true HRP20120695T1 (hr) | 2012-09-30 |
Family
ID=37623842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120695TT HRP20120695T1 (hr) | 2005-08-19 | 2012-09-04 | 8-supstituirani benzoazepini kao modulatori toll-u sličnog receptora |
Country Status (31)
Country | Link |
---|---|
US (2) | US8153622B2 (is) |
EP (3) | EP1940797B1 (is) |
JP (1) | JP5138592B2 (is) |
KR (2) | KR101442846B1 (is) |
CN (6) | CN101309906A (is) |
AP (1) | AP2008004386A0 (is) |
AU (1) | AU2006283620B2 (is) |
BR (1) | BRPI0614941B8 (is) |
CA (3) | CA2865331C (is) |
CR (2) | CR9809A (is) |
DK (1) | DK1940797T3 (is) |
EA (1) | EA018543B1 (is) |
EC (1) | ECSP088292A (is) |
ES (1) | ES2391031T3 (is) |
HK (1) | HK1122017A1 (is) |
HR (1) | HRP20120695T1 (is) |
IL (2) | IL189467A (is) |
MA (1) | MA29838B1 (is) |
MX (1) | MX2008002141A (is) |
MY (1) | MY146567A (is) |
NO (1) | NO342587B1 (is) |
NZ (1) | NZ565907A (is) |
PL (1) | PL1940797T3 (is) |
PT (1) | PT1940797E (is) |
RS (1) | RS52447B (is) |
SI (1) | SI1940797T1 (is) |
TN (1) | TNSN08076A1 (is) |
TW (2) | TW201402124A (is) |
UA (1) | UA92754C2 (is) |
WO (1) | WO2007024612A2 (is) |
ZA (1) | ZA200802496B (is) |
Families Citing this family (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI382019B (zh) * | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
CA2732437C (en) * | 2008-08-01 | 2017-11-21 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
WO2010054215A1 (en) | 2008-11-06 | 2010-05-14 | Ventirx Pharmaceuticals, Inc. | Methods of synthesis of benzazepine derivatives |
DK2467377T3 (en) | 2009-08-18 | 2017-04-03 | Ventirx Pharmaceuticals Inc | SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS |
AU2010284241B2 (en) | 2009-08-18 | 2016-11-10 | Array Biopharma, Inc. | Substituted benzoazepines as Toll-like receptor modulators |
CN103209696B (zh) | 2010-04-21 | 2016-02-24 | 文蒂雷克斯药品公司 | 增强抗体依赖性细胞的细胞毒性的方法 |
EA023397B1 (ru) | 2010-05-26 | 2016-05-31 | Селекта Байосайенсиз, Инк. | Комбинированные вакцины с синтетическими наноносителями |
WO2012024397A2 (en) * | 2010-08-17 | 2012-02-23 | Albany Molecular Research, Inc. | 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
US20120219615A1 (en) * | 2010-10-01 | 2012-08-30 | The Trustees Of The University Of Pennsylvania | Therapeutic Use of a TLR Agonist and Combination Therapy |
RU2587061C2 (ru) * | 2010-10-01 | 2016-06-10 | Вентиркс Фармасьютикалз, Инк. | Способы лечения аллергических заболеваний |
WO2012061717A1 (en) | 2010-11-05 | 2012-05-10 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
GB201022049D0 (en) * | 2010-12-29 | 2011-02-02 | Imp Innovations Ltd | Methods |
PL2663550T4 (pl) * | 2011-01-12 | 2017-07-31 | Ventirx Pharmaceuticals, Inc. | Podstawione benzoazepiny jako modulatory receptora toll-podobnego |
PL2663555T4 (pl) | 2011-01-12 | 2017-08-31 | Ventirx Pharmaceuticals, Inc. | Podstawione benzoazepiny jako modulatory receptora toll-podobnego |
RS60191B1 (sr) | 2011-04-08 | 2020-06-30 | Janssen Sciences Ireland Unlimited Co | Derivati pirimidina za tretman virusnih infekcija |
CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
US9868955B2 (en) | 2012-09-29 | 2018-01-16 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
US9228184B2 (en) | 2012-09-29 | 2016-01-05 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
SG11201503718QA (en) * | 2012-12-11 | 2015-06-29 | Hoffmann La Roche | Dimeric compounds |
KR101482999B1 (ko) * | 2013-06-17 | 2015-01-14 | 순천향대학교 산학협력단 | 톨-유사 수용체(tlr)에 의해 유도되는 trif-의존성 신호전달 경로의 억제제로서의 (e)-1-(2-(2-니트로 비닐)페닐)피롤리딘(nvpp)을 유효성분으로 포함하는 항염증제 |
AU2015205755C1 (en) | 2014-01-10 | 2020-08-13 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for immunotherapy |
AR100137A1 (es) | 2014-04-22 | 2016-09-14 | Hoffmann La Roche | Compuestos 4-amino-imidazoquinolina |
CN112546231A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
KR102462743B1 (ko) | 2014-07-09 | 2022-11-02 | 버디 바이오파마슈티칼즈, 인크. | 종양 치료용 항-pd-l1 조합 |
CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
MX2017007955A (es) | 2014-12-16 | 2018-02-19 | Celgene Corp | Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas. |
WO2016096778A1 (en) * | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Benzazepine sulfonamide compounds |
PT3321265T (pt) | 2015-03-04 | 2020-07-07 | Gilead Sciences Inc | Compostos 4,6-diamino-pirido[3,2-d]pirimidina compounds e a sua utilização como moduladores de receptores do tipo toll |
LT3265458T (lt) * | 2015-03-06 | 2019-03-12 | F. Hoffmann-La Roche Ag | Benzazepino dikarboksamido junginiai |
WO2017001307A1 (en) | 2015-06-30 | 2017-01-05 | F. Hoffmann-La Roche Ag | Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection |
MA42684A (fr) | 2015-08-26 | 2018-07-04 | Gilead Sciences Inc | Modulateurs deutérés du récepteur toll |
MA42818A (fr) | 2015-09-15 | 2018-07-25 | Gilead Sciences Inc | Modulateurs de récepteurs de type toll pour le traitement du vih |
EP3350168B1 (en) | 2015-09-17 | 2019-12-18 | H. Hoffnabb-La Roche Ag | Sulfinylphenyl or sulfonimidoylphenyl benzazepines |
US20180303845A1 (en) | 2015-11-02 | 2018-10-25 | Ventirx Pharmaceuticals, Inc. | Use of tlr8 agonists to treat cancer |
WO2017106346A2 (en) | 2015-12-15 | 2017-06-22 | Gilead Sciences, Inc. | Human immunodeficiency virus neutralizing antibodies |
CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
CN115554406A (zh) | 2016-01-07 | 2023-01-03 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-cd20组合 |
JP7022702B2 (ja) * | 2016-05-23 | 2022-02-18 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 第二級アミド基を有するベンズアゼピンジカルボキサミド化合物 |
JP6918838B2 (ja) * | 2016-05-23 | 2021-08-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 第三級アミド基を有するベンズアゼピンジカルボキサミド化合物 |
BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
US11738013B2 (en) | 2016-05-27 | 2023-08-29 | Gilead Sciences, Inc. | Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors |
JP7012668B2 (ja) | 2016-06-12 | 2022-02-14 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物 |
WO2018002319A1 (en) | 2016-07-01 | 2018-01-04 | Janssen Sciences Ireland Uc | Dihydropyranopyrimidines for the treatment of viral infections |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
JP6746776B2 (ja) | 2016-09-02 | 2020-08-26 | ギリアード サイエンシーズ, インコーポレイテッド | Toll様受容体調節剤化合物 |
ES2912945T3 (es) | 2016-09-29 | 2022-05-30 | Janssen Sciences Ireland Unlimited Co | Profármacos de pirimidina para el tratamiento de infecciones virales y otras enfermedades |
BR112019007450A2 (pt) | 2016-10-14 | 2020-07-07 | Precision Biosciences, Inc. | meganucleases modificadas específicas para sequências de reconhecimento no genoma do vírus da hepatite b |
TWI714820B (zh) | 2017-01-31 | 2021-01-01 | 美商基利科學股份有限公司 | 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型 |
JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
KR20200031560A (ko) | 2017-03-15 | 2020-03-24 | 실버백 테라퓨틱스, 인크. | 벤즈아제핀 화합물, 접합체, 및 그의 용도 |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
EP3641771A4 (en) | 2017-06-23 | 2020-12-16 | Birdie Biopharmaceuticals, Inc. | PHARMACEUTICAL COMPOSITIONS |
AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
CA3073376C (en) | 2017-08-22 | 2022-07-12 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
CN109694351B (zh) * | 2017-10-23 | 2020-07-28 | 江苏恒瑞医药股份有限公司 | 苯并氮杂*衍生物、其制备方法及其在医药上的应用 |
WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
CN109721597B (zh) * | 2017-10-30 | 2021-05-14 | 上海迪诺医药科技有限公司 | 吡啶并氮杂卓衍生物、其药物组合物及应用 |
AU2018385693A1 (en) | 2017-12-15 | 2020-06-18 | Silverback Therapeutics, Inc. | Antibody construct-drug conjugate for the treatment of hepatitis |
WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
JP7083398B2 (ja) | 2018-02-15 | 2022-06-10 | ギリアード サイエンシーズ, インコーポレイテッド | ピリジン誘導体およびhiv感染を処置するためのその使用 |
CA3175384A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection |
CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
CA3093888A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
JP7126573B2 (ja) | 2018-07-03 | 2022-08-26 | ギリアード サイエンシーズ, インコーポレイテッド | HIV gp120を標的化する抗体および使用方法 |
BR112020026890A2 (pt) | 2018-07-03 | 2021-03-30 | Jiangsu Hengrui Medicine Co., Ltd. | Derivado de piridopirimidina, método de preparação do mesmo e uso médico do mesmo |
EP3817818A1 (en) | 2018-07-06 | 2021-05-12 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
CN112384505A (zh) | 2018-07-06 | 2021-02-19 | 吉利德科学公司 | 治疗性的杂环化合物 |
EP4234030A3 (en) | 2018-07-13 | 2023-10-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
KR20210033492A (ko) | 2018-07-16 | 2021-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
EP3849615A1 (en) | 2018-09-12 | 2021-07-21 | Silverback Therapeutics, Inc. | Compositions for the treatment of disease with immune stimulatory conjugates |
WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
LT3873903T (lt) | 2018-10-31 | 2024-05-10 | Gilead Sciences, Inc. | Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai |
CA3116347A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
WO2020176505A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
WO2020176510A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチドおよびそのプロドラッグ |
WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
CN114008029A (zh) | 2019-06-18 | 2022-02-01 | 爱尔兰詹森科学公司 | 用于治疗病毒感染和另外的疾病的喹唑啉前药 |
WO2020255019A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative |
US20220305115A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
BR112021025699A2 (pt) | 2019-06-19 | 2022-03-03 | Silverback Therapeutics Inc | Anticorpos anti-mesotelina e imunoconjugados dos mesmos |
BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
TW202115056A (zh) | 2019-06-28 | 2021-04-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
CN114667134A (zh) | 2019-08-15 | 2022-06-24 | 希沃尔拜克治疗公司 | 苯并氮杂䓬缀合物的制剂及其用途 |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
CN117843811A (zh) | 2019-09-30 | 2024-04-09 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
KR20220085796A (ko) | 2019-10-18 | 2022-06-22 | 포티 세븐, 인코포레이티드 | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
CN114727999A (zh) | 2019-11-26 | 2022-07-08 | 吉利德科学公司 | 用于预防hiv的衣壳抑制剂 |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
KR20220131918A (ko) | 2019-12-24 | 2022-09-29 | 카나 바이오사이언스, 인코포레이션 | 다이아실글리세롤 키나제 조절 화합물 |
AU2020416484A1 (en) | 2020-01-02 | 2022-08-25 | Jiangsu Hengrui Medicine Co., Ltd. | Crystal form of pyridopyrimidine derivative and preparation method thereof |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
WO2021177679A1 (ko) | 2020-03-02 | 2021-09-10 | 성균관대학교산학협력단 | 병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법 |
TW202200161A (zh) | 2020-03-20 | 2022-01-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
IL297327A (en) | 2020-05-01 | 2022-12-01 | Gilead Sciences Inc | 4,2-deoxypyrimidine compounds that inhibit cd73 |
EP4153181A1 (en) | 2020-05-21 | 2023-03-29 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
US11680064B2 (en) | 2020-06-25 | 2023-06-20 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
IL299508A (en) | 2020-07-01 | 2023-02-01 | Ars Pharmaceuticals Inc | Name of the invention: antibody conjugates against ASGR1 and their uses |
JP2023536945A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 動力学的に作用するアジュバントアンサンブル |
EP4194006A1 (en) | 2020-08-04 | 2023-06-14 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途 |
CN116194144A (zh) | 2020-08-07 | 2023-05-30 | 吉利德科学公司 | 膦酰胺核苷酸类似物的前药及其药物用途 |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
WO2022103758A1 (en) | 2020-11-11 | 2022-05-19 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
CN117279664A (zh) | 2021-04-10 | 2023-12-22 | 普方生物制药美国公司 | Folr1结合剂、其偶联物及其使用方法 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
EP4326768A1 (en) | 2021-04-23 | 2024-02-28 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
JP2024518558A (ja) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ, インコーポレイテッド | TLR8調節化合物と抗HBV siRNA治療薬との組合せ |
TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用FLT3L—Fc融合蛋白之方法 |
AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
TW202342447A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於hiv病毒感染之治療性化合物 |
WO2023102239A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
TW202342448A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於hiv病毒感染之治療性化合物 |
US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros鋅指家族降解劑及其用途 |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4002610A (en) | 1975-09-22 | 1977-01-11 | Mcneil Laboratories, Incorporated | 2-Aminobenzodiazepine-5-ones |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
JPS6487631A (en) | 1987-09-28 | 1989-03-31 | Idemitsu Petrochemical Co | Production of polyarylene sulfide |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
GB8920519D0 (en) | 1989-09-11 | 1989-10-25 | Rhone Poulenc Ltd | New compositions of matter |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
ATE216366T1 (de) * | 1996-08-16 | 2002-05-15 | Pfizer | 2-aminobenzazepin-derivate und ihre verwendung für die behandlung von immunosuppression |
CN1549726A (zh) * | 2000-07-31 | 2004-11-24 | 耶鲁大学 | 先天性免疫系统指导的疫苗 |
KR20040099418A (ko) * | 2002-04-08 | 2004-11-26 | 다케다 야쿠힌 고교 가부시키가이샤 | 중증 패혈증 예방 치료제 |
WO2003105666A2 (en) * | 2002-06-12 | 2003-12-24 | Biogen, Inc. | Method of treating ischemia reperfusion injury using adenosine receptor antagonists |
US20040213264A1 (en) | 2003-04-25 | 2004-10-28 | Nortel Networks Limited | Service class and destination dominance traffic management |
EA200600069A1 (ru) * | 2003-06-20 | 2006-08-25 | Коли Фармасьютикал Гмбх | Низкомолекулярные антагонисты toll-подобных рецепторов (tlr) |
JP2007509987A (ja) | 2003-10-31 | 2007-04-19 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答調節剤化合物による好中球活性化 |
US20050226878A1 (en) | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
US8940755B2 (en) | 2003-12-02 | 2015-01-27 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
US20090270443A1 (en) | 2004-09-02 | 2009-10-29 | Doris Stoermer | 1-amino imidazo-containing compounds and methods |
TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
WO2010054215A1 (en) | 2008-11-06 | 2010-05-14 | Ventirx Pharmaceuticals, Inc. | Methods of synthesis of benzazepine derivatives |
AU2010284241B2 (en) | 2009-08-18 | 2016-11-10 | Array Biopharma, Inc. | Substituted benzoazepines as Toll-like receptor modulators |
DK2467377T3 (en) | 2009-08-18 | 2017-04-03 | Ventirx Pharmaceuticals Inc | SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS |
-
2006
- 2006-08-10 TW TW102117584A patent/TW201402124A/zh unknown
- 2006-08-10 TW TW095129414A patent/TWI404537B/zh not_active IP Right Cessation
- 2006-08-17 EP EP06801705A patent/EP1940797B1/en active Active
- 2006-08-17 BR BRPI0614941A patent/BRPI0614941B8/pt active IP Right Grant
- 2006-08-17 CA CA2865331A patent/CA2865331C/en active Active
- 2006-08-17 RS RS20120384A patent/RS52447B/en unknown
- 2006-08-17 US US12/064,193 patent/US8153622B2/en active Active
- 2006-08-17 ES ES06801705T patent/ES2391031T3/es active Active
- 2006-08-17 EA EA200800634A patent/EA018543B1/ru unknown
- 2006-08-17 MX MX2008002141A patent/MX2008002141A/es active IP Right Grant
- 2006-08-17 PT PT06801705T patent/PT1940797E/pt unknown
- 2006-08-17 UA UAA200803390A patent/UA92754C2/ru unknown
- 2006-08-17 PL PL06801705T patent/PL1940797T3/pl unknown
- 2006-08-17 EP EP20100184139 patent/EP2322510A3/en not_active Ceased
- 2006-08-17 MY MYPI20080300A patent/MY146567A/en unknown
- 2006-08-17 JP JP2008527127A patent/JP5138592B2/ja active Active
- 2006-08-17 CN CNA2006800380964A patent/CN101309906A/zh active Pending
- 2006-08-17 EP EP16157513.9A patent/EP3081558A1/en not_active Withdrawn
- 2006-08-17 CN CN201510118046.8A patent/CN104803915A/zh active Pending
- 2006-08-17 KR KR1020087006590A patent/KR101442846B1/ko active IP Right Grant
- 2006-08-17 WO PCT/US2006/032098 patent/WO2007024612A2/en active Application Filing
- 2006-08-17 CN CN201810884424.7A patent/CN109096192A/zh active Pending
- 2006-08-17 NZ NZ565907A patent/NZ565907A/en not_active IP Right Cessation
- 2006-08-17 AU AU2006283620A patent/AU2006283620B2/en not_active Ceased
- 2006-08-17 SI SI200631420T patent/SI1940797T1/sl unknown
- 2006-08-17 CN CN201510165871.3A patent/CN104910072A/zh active Pending
- 2006-08-17 AP AP2008004386A patent/AP2008004386A0/xx unknown
- 2006-08-17 CA CA3003143A patent/CA3003143A1/en not_active Abandoned
- 2006-08-17 CN CN201510192094.1A patent/CN104945323A/zh active Pending
- 2006-08-17 KR KR1020137016949A patent/KR20130082182A/ko not_active Application Discontinuation
- 2006-08-17 DK DK06801705.2T patent/DK1940797T3/da active
- 2006-08-17 CA CA2619581A patent/CA2619581C/en active Active
- 2006-08-17 CN CN201810884657.7A patent/CN109096193A/zh active Pending
-
2008
- 2008-02-12 IL IL189467A patent/IL189467A/en active IP Right Grant
- 2008-02-18 TN TNP2008000076A patent/TNSN08076A1/en unknown
- 2008-03-12 CR CR9809A patent/CR9809A/es unknown
- 2008-03-18 EC EC2008008292A patent/ECSP088292A/es unknown
- 2008-03-18 NO NO20081425A patent/NO342587B1/no unknown
- 2008-03-18 MA MA30762A patent/MA29838B1/fr unknown
- 2008-03-18 ZA ZA200802496A patent/ZA200802496B/xx unknown
- 2008-12-04 HK HK08113230.5A patent/HK1122017A1/xx not_active IP Right Cessation
-
2012
- 2012-03-07 US US13/414,579 patent/US8304407B2/en active Active
- 2012-09-04 HR HRP20120695TT patent/HRP20120695T1/hr unknown
-
2013
- 2013-03-24 IL IL225446A patent/IL225446A0/en unknown
- 2013-06-25 CR CR20130321A patent/CR20130321A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120695T1 (hr) | 8-supstituirani benzoazepini kao modulatori toll-u sličnog receptora | |
UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
TW200734322A (en) | Indole derivatives exhibiting PGD2 receptor antagonism | |
TW200744587A (en) | Azaindole derivatives exhibiting PGD2 receptor antagonism | |
AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
AR064319A1 (es) | Compuestos y composiciones farmaceuticas derivadas de sulfonamida ciclicos, proceso de preparacion y usos en el tratamiento de trastornos vasomotrices, sexuales, gastrointestinales y otros | |
MX2009010024A (es) | Nuevo compuesto de adenina. | |
TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
RS107504A (en) | Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compostions including the same, and methods for their use | |
ECSP066760A (es) | Derivado de 4-oxopirimidina de anillos condensados | |
NZ593110A (en) | pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS | |
ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
UA97639C2 (ru) | ОКТАГИДРОПИРОЛО[3,4-b]ПИРРОЛЬНЫЕ ПРОИЗВОДНЫЕ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ ГИСТАМИНА-3 | |
WO2002000650A3 (en) | Novel compounds possessing antibacterial, antifungal or antitumor activity | |
IN2012DN01325A (is) | ||
TW200800938A (en) | Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism | |
EA201001015A1 (ru) | Карбамоиловые соединения в качестве ингибиторов dgat1 190 | |
PE20020406A1 (es) | 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS 2,6-DISUSTITUIDAS COMO INHIBIDORES DE LAS PROTEINAS CINASAS | |
MXPA06002296A (es) | Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos. | |
MX2009012885A (es) | Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco | |
RS49906B (sr) | Benzociklohepteni, postupak za njihovo dobijanje, farmaceutski preparati koji ove sadrže kao i njihova primena za izradu lekova | |
MX2007005709A (es) | Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos. | |
UA100003C2 (ru) | Соединения 1,2,4,5-тетрагидро-3н-бензазепина, способ их получения и фармацевтическая композиция, которая их содержит | |
EA201790713A1 (ru) | N-АЛКИЛАРИЛ-5-ОКСОАРИЛОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛЬНЫЕ НЕГАТИВНЫЕ АЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ NR2B | |
ECSP14013296A (es) | Derivados de etinilo |